NasdaqGS:DNLIBiotechs
Why Denali Therapeutics (DNLI) Is Up 8.2% After Selling Its Priority Review Voucher For $195 Million
Denali Therapeutics Inc. previously announced it had entered into a definitive agreement to sell its FDA Rare Pediatric Disease Priority Review Voucher for US$195,000,000 in cash, following the accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome.
The move converts a one-time regulatory award into substantial non-dilutive funding, giving Denali additional flexibility to progress its lysosomal storage and neurodegenerative disease programs without issuing new equity.
We’ll...